Gene therapy using SV40-derived vectors: what does the future hold?
about
Role of Oxidative Stress in HIV-1-Associated Neurocognitive Disorder and Protection by Gene Delivery of Antioxidant EnzymesRole of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damageDelivery of novel macromolecular drugs against HIV-1.In vivo gene transfer into rat bone marrow progenitor cells using rSV40 viral vectors.Versatility of gene therapy vectors through viruses.Oxidative Stress Is Associated with Neuroinflammation in Animal Models of HIV-1 Tat Neurotoxicity.HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stressGene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.A rat model of human immunodeficiency virus 1 encephalopathy using envelope glycoprotein gp120 expression delivered by SV40 vectors.Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication.Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth.Exploiting hepatitis C virus activation of NFkappaB to deliver HCV-responsive expression of interferons alpha and gamma.Efficient CNS gene delivery by intravenous injection.HIV-1 proprotein processing as a target for gene therapy.Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe.Intracisternal rSV40 administration provides effective pan-CNS transgene expression.SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.Blood-brain barrier abnormalities caused by HIV-1 gp120: mechanistic and therapeutic implications.
P2860
Q26829535-6C0440C0-291F-4585-A546-66DEABB505B9Q28576511-FEE51FEB-D859-4775-8442-C9C724BD3935Q34452681-45460697-8AD8-4CEA-8665-E2371B5E3CB8Q35848397-B446D95F-8E4C-4F93-B5E6-4D81C3292C83Q36150489-4F98FDAA-F75D-40DC-A31C-F26137850906Q36335033-6AD40839-15E6-4F04-A129-DE46BE41DFABQ36450103-33991133-D7C9-4BB1-BA7F-1670EAD91229Q36450108-ED11F4A1-A001-48BE-9C64-4562AE3DA0A5Q36458373-4E3E14EF-50CB-4837-BF04-612238480E80Q39683291-053A23FE-5AFA-4055-B852-105538726991Q40228737-48A581AB-1AD4-4DD0-A15A-9B29DAB506A2Q40632797-DCEDBD43-9C5E-4A17-AC5D-782048C184B6Q42856452-D1758B81-12B2-49B4-822A-7E55E6B4B97FQ44351237-401922A2-1B8C-4819-9195-00FF28D13815Q45867822-A72AA096-219D-4C1E-B052-B4A1190EF9C4Q45870327-B0F74049-70FD-4F71-AEC4-D9774108BA1CQ45878407-87B5CC41-7EBE-4F92-A5E3-7E545F709658Q52623530-C75A8C33-F3E9-42D7-B7E7-0EAD1962E5D9
P2860
Gene therapy using SV40-derived vectors: what does the future hold?
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Gene therapy using SV40-derived vectors: what does the future hold?
@ast
Gene therapy using SV40-derived vectors: what does the future hold?
@en
type
label
Gene therapy using SV40-derived vectors: what does the future hold?
@ast
Gene therapy using SV40-derived vectors: what does the future hold?
@en
prefLabel
Gene therapy using SV40-derived vectors: what does the future hold?
@ast
Gene therapy using SV40-derived vectors: what does the future hold?
@en
P2860
P1476
Gene therapy using SV40-derived vectors: what does the future hold?
@en
P2093
Strayer DS
P2860
P304
P356
10.1002/(SICI)1097-4652(199912)181:3<375::AID-JCP1>3.0.CO;2-8
P577
1999-12-01T00:00:00Z